Literature DB >> 27849375

SIMVASTATIN DECREASES SEX HORMONE LEVELS IN MALE RATS.

Xiujuan Zhang, Jia Li, Xiaoming Zhou, Qingbo Guan, Jiajun Zhao, Ling Gao, Chunxiao Yu, Yong Wang, Changting Zuo.   

Abstract

OBJECTIVE: Statins can inhibit therate-limiting enzyme hydroxymethyl glutaric acid-coenzyme A reductase to reduce cholesterol biosynthesis, and they are used frequently in the clinic. Cholesterol is also a precursor for sex hormones. However, it is not clear whether statins can affect sex hormone levels. The aim of this study was to investigate the effect of long-term use of statins on sex hormone levels in vivo.
METHODS: Forty male Sprague-Dawley rats were randomly divided into four groups. Three simvastatin groups were administered different doses of simvastatin intragastrically daily (4, 8, or 16 mg/kg/day, n = 10). The control group was administered vehicle intragastrically daily (n = 10). The serum lipid spectrum and testosterone, estradiol, follicle-stimulating hormone (FSH), and luteinizing hormone (LH) levels were measured before (0 weeks) and after 20 and 40 weeks of simvastatin administration.
RESULTS: In the control group, there were no statistically significant differences between lipid levels, liver function, or sex hormone levels before and after intragastric administration. Compared with the previous intragastric administration group, there was no obvious change in liver function with different doses of simvastatin. However, serum levels of total cholesterol, low-density-lipoprotein cholesterol, triglycerides, testosterone, estradiol, and progesterone were markedly decreased in a dose- and time-dependent manner. By contrast, the levels of FSH and LH were significantly higher, showing feedback regulation.
CONCLUSION: Long-term simvastatin intake reduces serum testosterone, estradiol, and progesterone levels in male rats. ABBREVIATIONS: HMG-CoA = hydroxymethyl glutaric acid CoA LDL = low-density lipoprotein LDL-C = low-density-lipoprotein cholesterol FSH = follicle-stimulating hormone LH = luteinizing hormone.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27849375     DOI: 10.4158/EP161274.OR

Source DB:  PubMed          Journal:  Endocr Pract        ISSN: 1530-891X            Impact factor:   3.443


  5 in total

1.  The use of purified rat Leydig cells complements the H295R screen to detect chemical-induced alterations in testosterone production.

Authors:  Nicole L Botteri Principato; Juan D Suarez; Susan C Laws; Gary R Klinefelter
Journal:  Biol Reprod       Date:  2018-02-01       Impact factor: 4.285

2.  Environment-wide association study to comprehensively test and validate associations between nutrition and lifestyle factors and testosterone deficiency: NHANES 1988-1994 and 1999-2004.

Authors:  D S Lopez; W Wulaningsih; K K Tsilidis; J Baillargeon; S B Williams; R Urban; S Rohrmann
Journal:  Hormones (Athens)       Date:  2020-02-19       Impact factor: 2.885

3.  Diagnosis of osteoporosis in statin-treated patients is dose-dependent.

Authors:  Michael Leutner; Caspar Matzhold; Luise Bellach; Carola Deischinger; Jürgen Harreiter; Stefan Thurner; Peter Klimek; Alexandra Kautzky-Willer
Journal:  Ann Rheum Dis       Date:  2019-09-26       Impact factor: 19.103

4.  Major Depressive Disorder (MDD) and Antidepressant Medication Are Overrepresented in High-Dose Statin Treatment.

Authors:  Leutner Michael; Matzhold Caspar; Kautzky Alexander; Kaleta Michaela; Thurner Stefan; Klimek Peter; Kautzky-Willer Alexandra
Journal:  Front Med (Lausanne)       Date:  2021-02-11

5.  Association between Osteoporosis and Previous Statin Use: A Nested Case-Control Study.

Authors:  So Young Kim; Dae Myoung Yoo; Chanyang Min; Ji Hee Kim; Mi Jung Kwon; Joo-Hee Kim; Hyo Geun Choi
Journal:  Int J Environ Res Public Health       Date:  2021-11-12       Impact factor: 3.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.